BMGF – Gates Foundation  [to 27 Oct 2018 ]
No new digest content identified.
Bill & Melinda Gates Medical Research Institute    [to 27 Oct 2018]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 27 Oct 2018 ]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
CEPI – Coalition for Epidemic Preparedness Innovations  [to 27 Oct 2018 ]
No new digest content identified.
EDCTP    [to 27 Oct 2018 ]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.
Emory Vaccine Center    [to 27 Oct 2018 ]
No new digest content identified.
European Medicines Agency  [to 27 Oct 2018 ]
News and press releases
No new digest content identified.
European Vaccine Initiative  [to 27 Oct 2018 ]
No new digest content identified.
FDA [to 27 Oct 2018 ]
October 23, 2018
FDA launches global operation to crack down on websites selling illegal, potentially dangerous drugs; including opioids

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, acted this week to target 465 websites that illegally sell potentially dangerous, unapproved versions of opioid, oncology and antiviral prescription drugs to U.S. consumers.

This effort was part of Operation Pangea XI, the eleventh annual International Internet Week of Action (IIWA). This is a global cooperative effort, led by Interpol, to combat the unlawful sale and distribution of illegal and potentially counterfeit medical products sold on the internet…
Fondation Merieux  [to 27 Oct 2018 ]
Mérieux Foundation co-organized event
Case Management working group / Global Task Force on Cholera Control (GTFCC)
November 5 – 6, 2018 – Les Pensieres Center for Global Health, Veyrier-du-Lac (France)
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)
Gavi [to 27 Oct 2018 ]
No new digest content identified.
GHIT Fund   [to 27 Oct 2018 ]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
Global Fund [to 27 Oct 2018 ]
Gavi and Global Fund Commit to Addressing Sexual Exploitation, Abuse and Harassment
19 October 2018
Hilleman Laboratories   [to 27 Oct 2018 ]
No new digest content identified.
Human Vaccines Project   [to 27 Oct 2018 ]
Towards a Universal Influenza Vaccine: Lessons from the Great Influenza Pandemic of 1918 to Now
November 15-16, 2018 I Nashville, TN
The Human Vaccines Project is hosting a scientific summit featuring prominent researchers and thought leaders to discuss cutting-edge influenza research. The 2-day meeting will bring together leading scientists, clinicians and public health specialists including: John Barry, James E. Crowe, Jr., Senator Bill Frist, and Laurie Garrett.  Find a full agenda at:
IAVI  [to 27 Oct 2018 ]
October 22, 2018
Antibody-based HIV Prevention: Preparing for Success
New partnership aims to make antibody prophylaxis for HIV more feasible and affordable.
By Mark Feinberg, M.D., Ph.D., President and CEO of IAVI
Among the topics being discussed at the biannual HIV Research for Prevention (R4P) conference now taking place in Madrid, antibodies are at the forefront. Researchers are discussing innovative approaches to induce protective antibodies against HIV by vaccination, as well as the potential for these antibodies to be used directly to prevent HIV infection.
Since 2009, when IAVI scientists and their partners were among the first to identify a new class of HIV-specific antibodies, hundreds of potent antibodies with the ability to neutralize a broad swath of HIV variants have been identified. These so-called broadly neutralizing antibodies (bNAbs) are now reinvigorating efforts to design vaccine immunogens. IAVI and its partners recently advanced one of these immunogens into clinical trials. This candidate was engineered using the latest tools of computational and structural biology by researchers at the IAVI Neutralizing Antibody Center at Scripps Research in La Jolla, California….
October 22, 2018
IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV
NEW YORK – October 22, 2018 – The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world’s largest vaccine manufacturer, today announced a strategic partnership to develop and manufacture affordable and accessible monoclonal antibody products for HIV and other global health challenges….
No new digest content identified.
IVAC  [to 27 Oct 2018 ]
No new digest content identified.
IVI   [to 27 Oct 2018 ]
No new digest content identified.
JEE Alliance  [to 27 Oct 2018 ]
The Alliance meets to discuss One Health, upcoming work and governance – and invites partners to join the network
Meeting, Advisory Group
Sustainable health security capacity building requires country ownership and a One Health and all hazards approach. The multi-partner Joint External Evaluation (JEE) supports collaboration across sectors such as animal and human health, agriculture, defense, development, environment, food safety, public safety, as well as tourism and trade.
On 5 November 2018, the JEE Alliance will meet in Bali, in the margins of the 5th Global Health Security Agenda Ministerial Meeting hosted by the Government of Indonesia.
The focus of the event will be twofold
:: A panel discussion on facilitating integration of One Health approach in national health security capacity building
:: Discussion on the Alliance work plan and the new Advisory Group for 2019…
MSF/Médecins Sans Frontières  [to 27 Oct 2018 ]
High prices restrict access to best drug-resistant tuberculosis treatment
Press Release   23 October 2018
MSF calls on US pharma corporation Johnson & Johnson to halve the price of the newer TB drug bedaquiline.
NIH  [to 27 Oct 2018 ]
October 23, 2018
NIH selects first scholars in pioneering program to enhance diversity within in-house research program
— Distinguished Scholars Program to augment diversity and inclusion in the biomedical workforce.

October 23, 2018
Amazon Web Services joins NIH’s STRIDES Initiative to harness latest cloud technologies for biomedical researchers
AWS is the second cloud service provider to join the STRIDES Initiative following Google Cloud.
Amazon Web Services (AWS) has joined the National Institutes of Health’s Science and Technology Research Infrastructure for Discovery, Experimentation, and Sustainability (STRIDES) Initiative. Launched in July 2018, the STRIDES Initiative aims to harness the power of commercial cloud computing for NIH biomedical researchers. Initially, NIH’s efforts will focus on making high-value data sets more accessible to researchers and experimenting with new ways to optimize technology-intensive research…
PATH  [to 27 Oct 2018 ]
No new digest content identified.
Sabin Vaccine Institute  [to 27 Oct 2018 ]
No new digest content identified.
UNAIDS [to 27 Oct 2018 ]
No new digest content identified.
UNICEF  [to 27 Oct 2018 ]
Selected Press Releases/Reports/Statements
Press release
An estimated 2,300 children traveling with migrant caravan in Mexico need protection and essential services – UNICEF

Press release
Sulawesi Earthquake & Tsunami: One month on from the disaster, thousands of children still homeless, out-of-school and in need of humanitarian support

Press release
UNICEF Airlifts 4.7 Million Doses of Measles, Rubella and Polio Vaccines for Children in Libya

Press release
New global commitment to primary health care for all at Astana conference
Declaration of Astana charts course to achieve universal health coverage, 40 years since declaration on primary health care in Alma-Ata

Vaccine Confidence Project  [to 27 Oct 2018 ]
Vaccine Confidence Project – Confidence Commentary
NEW REPORT: The State of Vaccine Confidence in the EU: 2018
Heidi Larson | 26 Oct, 2018
High confidence in vaccination programmes is crucial for maintaining high coverage rates, especially at levels that exceed those required for herd immunity. Across the European Union (EU), however, vaccine delays and refusals are contributing to declining immunisation rates in a number of countries and are leading to increases in disease outbreaks. Recent measles outbreaks – the highest in the EU for seven years – illustrate the immediate impact of declining coverage on disease outbreaks.
In this report  we assess the overall state of confidence in vaccines among the public in all 28 EU member states and among general practitioners (GP) in ten EU member states…
[See Milestones/Perspectives above for detail]
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 27 Oct 2018 ]
Vaccine Update for Providers
Newsletter – October 2018
Wellcome Trust  [to 27 Oct 2018 ]
News / Published: 24 October 2018
Naguib Kheraj to join our Board of Governors
Finance industry leader Naguib Kheraj will join the Wellcome Board of Governors in January 2019.
Naguib Kheraj is Deputy Chairman of Standard Chartered PLC – a major international bank – and Chairman of Rothesay Life, a specialist UK insurer. He is also a current member of Wellcome’s Investment Committee, which is responsible for reviewing and advising on Wellcome’s investment portfolio and strategy…
The Wistar Institute   [to 27 Oct 2018 ]
No new digest content identified.
World Organisation for Animal Health (OIE)   [to 27 Oct 2018 ]
No new digest content identified.

BIO    [to 27 Oct 2018 ]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 27 Oct 2018 ]
29 October 2018 to 31 October 2018
19th DCVMN Annual General Meeting
Kunming / China

WHO prequalifies new rotavirus vaccine
Geneva, 25th September 2018 – The World Health Organization prequalified Rotasil, an oral rotavirus vaccine produced by Serum Institute of India. Rotasil is the first Rotavirus vaccine with heat stable characteristics, which makes it particularly suitable for use in low-income countries, where weak infrastructure and frequent lack of electricity make refrigeration very difficult.
Rotavirus is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in parts of Africa and Asia. Because the condition is so widespread and serious, rotavirus vaccines should be included in all national immunization programmes and considered a priority, particularly in countries with high associated death rates, such as in south and south-eastern Asia and sub-Saharan Africa.

The addition of Rotasil to the WHO list of Prequalified vaccines will help to expand the global supply of rotavirus vaccines, increasing countries’ options to address the disease. It is also possible that it will reduce the price of available quality-assured vaccines through greater competition.

More info at

IFPMA   [to 27 Oct 2018 ]
No new digest content identified.
PhRMA    [to 27 Oct 2018 ]
No new digest content identified.
Industry Watch
:: Johnson & Johnson Announces Promising, Early-Stage Results for Tetravalent Mosaic-based HIV Preventive Vaccine Regimen
– TRAVERSE data add to body of clinical evidence supporting further study of Janssen’s investigational mosaic-based vaccine regimen –
MADRID, SPAIN, 22 October 2018 – Johnson & Johnson today announced the primary analysis of immune response data for a tetravalent mosaic-based preventive vaccine against HIV-1 infection in development at the Janssen Pharmaceutical Companies of Johnson & Johnson. In the early-stage, Phase 1/2a TRAVERSE study among HIV-negative volunteers, a vaccine regimen including a tetravalent (4-valent) mosaic viral vector was compared to a regimen containing a trivalent (3-valent) mosaic vector. At 28 weeks, the tetravalent mosaic-based vaccine was well tolerated and significantly enhanced the breadth of immune responses to different HIV-1 strains compared to the trivalent version. These Phase 1/2a data will be shared this week at the 2018 HIV Research for Prevention Conference (HIVR4P) in Madrid, Spain. The tetravalent vaccine is now in large-scale efficacy testing.

“We urgently need new prevention tools to turn the tide of the HIV pandemic, and an effective preventive vaccine would be a vital asset to help us achieve an HIV-free future,” said Hanneke Schuitemaker, Ph.D., Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V. “Our goal is to develop a universal vaccine that could be deployed against any strain of HIV circulating in the world.”

Developing an effective vaccine against HIV has proven challenging due in part to the significant global genetic diversity of the virus. Janssen’s investigational vaccine regimen contains mosaic immunogens (molecules capable of inducing an immune response) that have been created using genes from a wide variety of HIV-1 subtypes. Both the trivalent and tetravalent versions of the mosaic-based vaccine contain viral vectors that deliver immunogens designed to elicit immune responses against the three main proteins of HIV (Env, Pol and Gag). But the tetravalent formulation adds a fourth immunogen, which is Env-focused and designed to enhance the breadth of immune responses against HIV-1 subtypes.

These new TRAVERSE results build on encouraging safety and immune response results for the mosaic-based vaccine from the Phase 1/2a APPROACH study that were shared at the 22nd International AIDS Conference (AIDS 2018). Early findings from TRAVERSE and APPROACH were critical in enabling the first large-scale efficacy study for a mosaic-based vaccine regimen, HVTN 705/HPX2008 (also known as ‘Imbokodo’), to commence in November 2017. This Phase 2b study is assessing a regimen based on the tetravalent vaccine that was first clinically evaluated in the TRAVERSE study. It aims to enroll 2,600 women aged 18-35 in five sub-Saharan African countries to determine whether the vaccine is safe and efficacious in reducing HIV-1 infection in this population.

Results from HVTN 705/HPX2008 are expected in 2021. Additional large-scale studies will be needed to support licensure of the mosaic-based vaccine regimen against HIV-1.